Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.59 |
| ▸ | HRH2 | P25021 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 4/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3359767 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2EPHX2HRH2ADRA1BOPRK1 | |
| SCHEMBL12875947 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2EPHX2HRH2ADRA1BOPRK1 | |
| SCHEMBL24208711 | 0.84 | TDP1 (0.55) | SMN1; SMN2EPHX2CXCR3MAOAHSD11B1 | |
| SCHEMBL3360579 | 0.81 | SMN1; SMN2 (0.97) | SMN1; SMN2EPHX2CXCR3KDM1AMAOA | |
| SCHEMBL3363980 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2EPHX2CXCR3KDM1A | |
| SCHEMBL3360454 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2EPHX2CXCR3KDM1AMAOA | |
| SCHEMBL9720812 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2EPHX2CXCR3 | |
| SCHEMBL12887817 | 0.81 | EPHX2 (0.49) | SMN1; SMN2EPHX2HRH2ADRA1BOPRK1 | |
| SCHEMBL3359980 | 0.80 | SLC6A2 (0.59) | SMN1; SMN2EPHX2HRH2OPRK1SLC6A3 | |
| SCHEMBL3358972 | 0.80 | KDM1A (0.54) | SMN1; SMN2EPHX2HRH2SLC6A3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105923-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | SHIONOGI & CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105923-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | HAAO, CYP4A11, CYP4F11 | SMN1; SMN2 4475/4885EPHX2 2050/4885HRH2 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.